{"id":"W3194203975","doi":"10.1182/blood.2021012082","title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology; National Cancer Institute; National Institute for Health and Care Research","keywords":"Ponatinib; Medicine; Internal medicine; Clinical endpoint; Adverse effect; Myeloid leukemia; Cohort; Confidence interval; Oncology; Nilotinib; Clinical trial; Imatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002205532,0.001750482,0.002362691,0.0003559563,0.0003773358,0.001189872,0.0008737323,0.001738287,0.006036934],"category_scores_gemma":[0.002252629,0.0006018265,0.001454635,0.0003911472,0.001032152,0.001658563,0.0004797753,0.00325052,0.001075561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000773092,"about_ca_system_score_gemma":0.001085747,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004430567,"about_ca_topic_score_gemma":0.001162248,"domain_scores_codex":[0.9990728,0.0004891899,0.00004720743,0.000178726,0.0000968859,0.0001152585],"domain_scores_gemma":[0.9991885,0.0001647777,0.0001917175,0.00007947632,0.00006586268,0.000309637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9527262,0.01307924,0.001314979,0.0006403249,0.001072968,0.000107987,0.00008475176,0.0006462067,0.004034908,0.000292358,0.002207395,0.02379261],"study_design_scores_gemma":[0.955902,0.04063166,0.001590712,0.00001186792,0.0001547263,0.00006124029,0.00001254921,0.0003259302,0.0002293387,0.000185238,0.0008812574,0.0000133847],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831255,0.003196744,0.0008744268,0.001078732,0.0004938213,0.006119125,0.001874516,0.0001782429,0.003058743],"genre_scores_gemma":[0.9821416,0.002386767,0.001743754,0.001662474,0.0004658625,0.006403606,0.002090193,0.00003659261,0.003069198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006036934,"threshold_uncertainty_score":0.02019554,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08930478020376911,"score_gpt":0.4306504869785546,"score_spread":0.3413457067747855,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}